Author:
Bertacchini Jessika,Heidari Nazanin,Mediani Laura,Capitani Silvano,Shahjahani Mohammad,Ahmadzadeh Ahmad,Saki Najmaldin
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Cellular and Molecular Neuroscience,Pharmacology,Molecular Biology,Molecular Medicine
Reference96 articles.
1. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL et al (2003) Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 3:590–603 (PubMed PMID: 12646949, Epub 2003/03/21. eng)
2. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8(8):627–644 (PubMed PMID: 19644473, Pubmed Central PMCID: PMC3142564, Epub 2009/08/01. eng)
3. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol cell Biol 11(5):329–341 (PubMed PMID: 20379207, Epub 2010/04/10. eng)
4. Salari F, Shahjahani M, Shahrabi S, Saki N (2014) Minimal residual disease in acute lymphoblastic leukemia: optimal methods and clinical relevance, pitfalls and recent approaches. Med Oncol (Northwood, Lond, Engl) 31(11):266 (PubMed PMID: 25287907, Epub 2014/10/08. eng)
5. Tasian SK, Teachey DT, Rheingold SR (2014) Targeting the PI3K/mTOR pathway in pediatric hematologic malignancies. Front Oncol. 4:108 (PubMed PMID: 24904824, Pubmed Central PMCID: PMC4032892, Epub 2014/06/07. eng)
Cited by
199 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献